{"id":353099,"date":"2026-11-18T15:37:22","date_gmt":"2026-11-18T10:07:22","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=353099"},"modified":"2026-11-18T15:37:22","modified_gmt":"2026-11-18T10:07:22","slug":"crude-oil-producer-pharmaceuticals-company-and-specialty-chemicals-maker-stocks-roadmap-steppeland-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/crude-oil-producer-pharmaceuticals-company-and-specialty-chemicals-maker-stocks-roadmap-steppeland-list\/","title":{"rendered":"3 Crude Oil Producer, Pharmaceuticals Company and Specialty Chemicals Maker Stocks With a Strong Future Roadmap: Oil India, Ajanta Pharma and Clean Science and Technology"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Oil India, Ajanta Pharma and Clean Science and Technology: ROE of 11.4% to 23.3% and FY22 to FY26 revenue CAGR of 7.3% to 12.9%. Prices as of 17 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three <strong>crude oil, drug maker and chemical stocks<\/strong> to watch are <strong>Oil India<\/strong>, <strong>Ajanta Pharma<\/strong> and <strong>Clean Science and Technology<\/strong>. Their <strong>return on equity<\/strong> ranges from <strong>11.4% to 23.3%<\/strong>, and their <strong>revenue compound annual growth<\/strong> from FY22 to FY26 ranges from 7.3% to 12.9%. Ajanta Pharma leads on both return on equity at 23.3% and revenue growth at 12.9% a year. Prices are based on the 17 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Crude oil, drug maker and chemical stocks let investors follow companies that serve a growing part of the Indian economy. Oil India, Ajanta Pharma and Clean Science and Technology cover a crude oil producer, a pharmaceuticals company and a specialty chemicals maker.<\/p>\n<p>This list covers three crude oil, drug maker and chemical stocks with complete current figures: Oil India, Ajanta Pharma and Clean Science and Technology. Every figure comes from the latest reported financials and the 17 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=crude-oil-producer-pharmaceuticals-company-and-specialty-chemicals-maker-stocks-roadmap-steppeland-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/crude-oil-producer-pharmaceuticals-company-and-specialty-chemicals-maker-stocks-roadmap-steppeland-list\/#What_Are_Crude_Oil_Drug_Maker_and_Chemical_Stocks\" title=\"What Are Crude Oil, Drug Maker and Chemical Stocks?\">What Are Crude Oil, Drug Maker and Chemical Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/crude-oil-producer-pharmaceuticals-company-and-specialty-chemicals-maker-stocks-roadmap-steppeland-list\/#Crude_Oil_Drug_Maker_and_Chemical_Stocks_at_a_Glance\" title=\"Crude Oil, Drug Maker and Chemical Stocks at a Glance\">Crude Oil, Drug Maker and Chemical Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/crude-oil-producer-pharmaceuticals-company-and-specialty-chemicals-maker-stocks-roadmap-steppeland-list\/#Why_Do_Crude_Oil_Drug_Maker_and_Chemical_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Crude Oil, Drug Maker and Chemical Stocks Have a Strong Roadmap in India?\">Why Do Crude Oil, Drug Maker and Chemical Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/crude-oil-producer-pharmaceuticals-company-and-specialty-chemicals-maker-stocks-roadmap-steppeland-list\/#Why_Oil_India_Features_Among_These_Crude_Oil_Drug_Maker_and_Chemical_Stocks\" title=\"Why Oil India Features Among These Crude Oil, Drug Maker and Chemical Stocks\">Why Oil India Features Among These Crude Oil, Drug Maker and Chemical Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/crude-oil-producer-pharmaceuticals-company-and-specialty-chemicals-maker-stocks-roadmap-steppeland-list\/#Why_Ajanta_Pharma_Features_Among_These_Crude_Oil_Drug_Maker_and_Chemical_Stocks\" title=\"Why Ajanta Pharma Features Among These Crude Oil, Drug Maker and Chemical Stocks\">Why Ajanta Pharma Features Among These Crude Oil, Drug Maker and Chemical Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/crude-oil-producer-pharmaceuticals-company-and-specialty-chemicals-maker-stocks-roadmap-steppeland-list\/#Why_Clean_Science_and_Technology_Features_Among_These_Crude_Oil_Drug_Maker_and_Chemical_Stocks\" title=\"Why Clean Science and Technology Features Among These Crude Oil, Drug Maker and Chemical Stocks\">Why Clean Science and Technology Features Among These Crude Oil, Drug Maker and Chemical Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/crude-oil-producer-pharmaceuticals-company-and-specialty-chemicals-maker-stocks-roadmap-steppeland-list\/#Oil_India_vs_Ajanta_Pharma_vs_Clean_Science_and_Technology_on_Key_Financials\" title=\"Oil India vs Ajanta Pharma vs Clean Science and Technology on Key Financials\">Oil India vs Ajanta Pharma vs Clean Science and Technology on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/crude-oil-producer-pharmaceuticals-company-and-specialty-chemicals-maker-stocks-roadmap-steppeland-list\/#Key_Risks_to_Check_Before_Investing_in_Crude_Oil_Drug_Maker_and_Chemical_Stocks\" title=\"Key Risks to Check Before Investing in Crude Oil, Drug Maker and Chemical Stocks\">Key Risks to Check Before Investing in Crude Oil, Drug Maker and Chemical Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/crude-oil-producer-pharmaceuticals-company-and-specialty-chemicals-maker-stocks-roadmap-steppeland-list\/#Final_Thoughts_on_Crude_Oil_Drug_Maker_and_Chemical_Stocks\" title=\"Final Thoughts on Crude Oil, Drug Maker and Chemical Stocks\">Final Thoughts on Crude Oil, Drug Maker and Chemical Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/crude-oil-producer-pharmaceuticals-company-and-specialty-chemicals-maker-stocks-roadmap-steppeland-list\/#What_are_crude_oil_drug_maker_and_chemical_stocks\" title=\"What are crude oil, drug maker and chemical stocks?\">What are crude oil, drug maker and chemical stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/crude-oil-producer-pharmaceuticals-company-and-specialty-chemicals-maker-stocks-roadmap-steppeland-list\/#Which_crude_oil_drug_maker_and_chemical_stocks_are_covered_in_this_list\" title=\"Which crude oil, drug maker and chemical stocks are covered in this list?\">Which crude oil, drug maker and chemical stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/crude-oil-producer-pharmaceuticals-company-and-specialty-chemicals-maker-stocks-roadmap-steppeland-list\/#Why_do_crude_oil_drug_maker_and_chemical_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do crude oil, drug maker and chemical stocks have a strong future roadmap in India?\">Why do crude oil, drug maker and chemical stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/crude-oil-producer-pharmaceuticals-company-and-specialty-chemicals-maker-stocks-roadmap-steppeland-list\/#How_has_Oil_India_performed_financially\" title=\"How has Oil India performed financially?\">How has Oil India performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/crude-oil-producer-pharmaceuticals-company-and-specialty-chemicals-maker-stocks-roadmap-steppeland-list\/#How_has_Ajanta_Pharma_performed_financially\" title=\"How has Ajanta Pharma performed financially?\">How has Ajanta Pharma performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/crude-oil-producer-pharmaceuticals-company-and-specialty-chemicals-maker-stocks-roadmap-steppeland-list\/#How_has_Clean_Science_and_Technology_performed_financially\" title=\"How has Clean Science and Technology performed financially?\">How has Clean Science and Technology performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/crude-oil-producer-pharmaceuticals-company-and-specialty-chemicals-maker-stocks-roadmap-steppeland-list\/#What_risks_should_investors_check_before_buying_crude_oil_drug_maker_and_chemical_stocks\" title=\"What risks should investors check before buying crude oil, drug maker and chemical stocks?\">What risks should investors check before buying crude oil, drug maker and chemical stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/crude-oil-producer-pharmaceuticals-company-and-specialty-chemicals-maker-stocks-roadmap-steppeland-list\/#Is_this_list_of_crude_oil_drug_maker_and_chemical_stocks_investment_advice\" title=\"Is this list of crude oil, drug maker and chemical stocks investment advice?\">Is this list of crude oil, drug maker and chemical stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Crude_Oil_Drug_Maker_and_Chemical_Stocks\"><\/span><strong>What Are Crude Oil, Drug Maker and Chemical Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Crude oil, drug maker and chemical stocks<\/strong> are listed companies that produce crude oil and natural gas from fields in Assam and other basins, make branded medicines for India and global markets, and make performance chemicals for cosmetics, paints and pharma. Their earnings depend on oil prices, medicine demand and chemical orders.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Crude_Oil_Drug_Maker_and_Chemical_Stocks_at_a_Glance\"><\/span><strong>Crude Oil, Drug Maker and Chemical Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/oil\/oil-india-ltd-share-price-today\">Oil India<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">433.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">72,563<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.65<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/ajantpharm\/ajanta-pharma-ltd-share-price-today\">Ajanta Pharma<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,312.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">41,241<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.06<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/clean\/clean-science-and-technology-ltd-share-price-today\">Clean Science and Technology<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">715.95<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8,080<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">34.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">35.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.00<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Clean Science and Technology trades at a <strong>P\/E<\/strong> below the industry P\/E, while Oil India and Ajanta Pharma trade above it, which reflects the growth the market already expects. Readers comparing crude oil, drug maker and chemical stocks should look at <strong>return on equity<\/strong> and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in crude oil, drug maker and chemical stocks can use the coming numbers to test whether growth is holding.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Crude_Oil_Drug_Maker_and_Chemical_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Crude Oil, Drug Maker and Chemical Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Crude oil, drug maker and chemical stocks<\/strong> have a strong roadmap in India because steady energy demand, rising demand for branded medicines and wider use of specialty chemicals keep widening the market for these companies.<\/p>\n<ul>\n<li><strong>Crude oil.<\/strong> The country needs home grown energy.<\/li>\n<li><strong>Pharmaceuticals.<\/strong> Doctors prescribe trusted brands.<\/li>\n<li><strong>Specialty chemicals.<\/strong> Brands need performance inputs.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Oil_India_Features_Among_These_Crude_Oil_Drug_Maker_and_Chemical_Stocks\"><\/span><strong>Why Oil India Features Among These Crude Oil, Drug Maker and Chemical Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the crude oil, drug maker and chemical stocks on this list, Oil India is a public sector company that explores for and produces crude oil and natural gas, mainly in Assam and other parts of the country, and it also operates a crude pipeline in the North East.<\/p>\n<p>The company has a return on equity of 11.4%, a debt to equity ratio of 0.65 and a <strong>market capitalisation<\/strong> of Rs 72,563 crore. The stock trades at a <strong>P\/E<\/strong> of 7.6, above the industry P\/E of 7.2.<\/p>\n<p>Revenue rose from Rs 27,048 crore in FY22 to Rs 35,877 crore in FY26, a compound annual growth rate of 7.3%. Net profit grew from Rs 7,040 crore in FY25 to Rs 7,551 crore in FY26, a rise of 7.3%. In the June 2026 quarter, revenue grew 47.0% year on year to Rs 13,236 crore, while net profit rose 96.8% to Rs 4,027 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The company is stepping up exploration and development spending and building a presence in refining and clean energy through its group companies. Steady production supports earnings and dividends.<\/p>\n<p><strong>What to watch:<\/strong> Track crude oil prices, production volumes and progress on new exploration blocks.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Ajanta_Pharma_Features_Among_These_Crude_Oil_Drug_Maker_and_Chemical_Stocks\"><\/span><strong>Why Ajanta Pharma Features Among These Crude Oil, Drug Maker and Chemical Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the oil producer, pharma brand and performance chemical shares on this list, Ajanta Pharma is a specialty pharmaceutical company that sells branded generics in India and in emerging markets across Asia and Africa, with a focus on ophthalmology, dermatology, cardiology and pain management, and also sells generics in the United States.<\/p>\n<p>Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%.<\/p>\n<p>In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P\/E of 36.3, above the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.<\/p>\n<p><strong>What to watch:<\/strong> Monitor the pace of new launches in branded markets and the momentum in the United States generics business.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Clean_Science_and_Technology_Features_Among_These_Crude_Oil_Drug_Maker_and_Chemical_Stocks\"><\/span><strong>Why Clean Science and Technology Features Among These Crude Oil, Drug Maker and Chemical Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Clean Science and Technology makes specialty chemicals including performance chemicals, pharma intermediates and FMCG chemicals using its own catalytic processes.<\/p>\n<p>In the June 2026 quarter, revenue grew 13.4% year on year to Rs 291 crore, while net profit rose 4.7% to Rs 73.3 crore. Revenue rose from Rs 715 crore in FY22 to Rs 989 crore in FY26, a compound annual growth rate of 8.5%.<\/p>\n<p>Net profit for FY26 was Rs 230 crore, a net margin of 23.2%. The company has a return on equity of 14.5%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 8,080 crore. The stock trades at a P\/E of 34.7, below the industry P\/E of 35.1.<\/p>\n<p><strong>Roadmap:<\/strong> The company uses cleaner, in-house developed processes that give it cost advantages in products such as MEHQ and guaiacol. It is adding new products and capacity, and carries no debt.<\/p>\n<p><strong>What to watch:<\/strong> Watch new product launches and capacity utilisation at its newer plants.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Oil_India_vs_Ajanta_Pharma_vs_Clean_Science_and_Technology_on_Key_Financials\"><\/span><strong>Oil India vs Ajanta Pharma vs Clean Science and Technology on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three crude oil, drug maker and chemical stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Oil India<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">27,048<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">35,877<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7.3%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7,551<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">21.0%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Ajanta Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,457<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,625<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.9%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,056<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.8%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Clean Science and Technology<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">715<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">989<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8.5%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">230<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.2%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Ajanta Pharma posts the highest return on equity in this group at 23.3%. Oil India has the largest FY26 revenue at Rs 35,877 crore, and Ajanta Pharma shows the fastest revenue growth with a 12.9% compound annual rate. A useful habit with <strong>crude oil, drug maker and chemical stocks<\/strong> is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several upstream oil, formulations and specialty chemicals stocks instead of one name, which keeps a single result from deciding the outcome.<\/p>\n<p>The June 2026 quarter, the latest reported, gives a fresh read on momentum:<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY27 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Year-on-Year Growth<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Oil India<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9,006<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13,236<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">47.0%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Ajanta Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,329<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,697<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">27.7%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Clean Science and Technology<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">256<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">291<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.4%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Crude_Oil_Drug_Maker_and_Chemical_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Crude Oil, Drug Maker and Chemical Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these crude oil, drug maker and chemical stocks, the main points are: Long-term oil producer, pharma brand and performance chemical shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Oil and gas prices.<\/strong> Earnings follow crude oil, gas and refining margins.<\/li>\n<li><strong>Regulatory approvals.<\/strong> Plant inspections and approvals can affect supplies.<\/li>\n<li><strong>Raw material and energy costs.<\/strong> Input prices can move margins in chemicals.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter crude oil, drug maker and chemical stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Crude_Oil_Drug_Maker_and_Chemical_Stocks\"><\/span><strong>Final Thoughts on Crude Oil, Drug Maker and Chemical Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Crude oil, drug maker and chemical stocks<\/strong> reward investors who follow demand trends, order books and margins together. Oil India, Ajanta Pharma and Clean Science and Technology each have a clear plan to grow. Based on the 17 November 2026 close, Oil India trades at Rs 433.5, Ajanta Pharma at Rs 3,312.5 and Clean Science and Technology at Rs 715.95. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these crude oil, drug maker and chemical stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track crude oil, drug maker and chemical stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_crude_oil_drug_maker_and_chemical_stocks\"><\/span><strong>What are crude oil, drug maker and chemical stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Crude oil, drug maker and chemical stocks are listed companies that produce crude oil and natural gas from fields in Assam and other basins, make branded medicines for India and global markets, and make performance chemicals for cosmetics, paints and pharma. Their earnings depend on oil prices, medicine demand and chemical orders. This list looks at three of them, Oil India, Ajanta Pharma and Clean Science and Technology, using reported FY22 to FY26 financials and the 17 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_crude_oil_drug_maker_and_chemical_stocks_are_covered_in_this_list\"><\/span><strong>Which crude oil, drug maker and chemical stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Oil India, Ajanta Pharma and Clean Science and Technology. Based on the 17 November 2026 close, Oil India traded at Rs 433.5, Ajanta Pharma at Rs 3,312.5 and Clean Science and Technology at Rs 715.95. Their return on equity ranges from <strong>11.4% to 23.3%<\/strong>, and their <strong>revenue compound annual growth<\/strong> from FY22 to FY26 ranges from 7.3% to 12.9%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_crude_oil_drug_maker_and_chemical_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do crude oil, drug maker and chemical stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> <strong>Crude oil, drug maker and chemical stocks<\/strong> have a strong roadmap in India because steady energy demand, rising demand for branded medicines and wider use of specialty chemicals keep widening the market for these companies. The main drivers are as follows. Crude oil. The country needs home grown energy. Pharmaceuticals. Doctors prescribe trusted brands. Specialty chemicals. Brands need performance inputs. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Oil_India_performed_financially\"><\/span><strong>How has Oil India performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 27,048 crore in FY22 to Rs 35,877 crore in FY26, a compound annual growth rate of 7.3%. Net profit grew from Rs 7,040 crore in FY25 to Rs 7,551 crore in FY26, a rise of 7.3%. In the June 2026 quarter, revenue grew 47.0% year on year to Rs 13,236 crore, while net profit rose 96.8% to Rs 4,027 crore. The company has a return on equity of 11.4%, a debt to equity ratio of 0.65 and a market capitalisation of Rs 72,563 crore. The stock trades at a P\/E of 7.6, above the industry P\/E of 7.2. Looking ahead, the company is stepping up exploration and development spending and building a presence in refining and clean energy through its group companies. Steady production supports earnings and dividends.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Ajanta_Pharma_performed_financially\"><\/span><strong>How has Ajanta Pharma performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P\/E of 36.3, above the industry P\/E of 36.0. Looking ahead, the company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Clean_Science_and_Technology_performed_financially\"><\/span><strong>How has Clean Science and Technology performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 715 crore in FY22 to Rs 989 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 230 crore, a net margin of 23.2%. In the June 2026 quarter, revenue grew 13.4% year on year to Rs 291 crore, while net profit rose 4.7% to Rs 73.3 crore. The company has a return on equity of 14.5%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 8,080 crore. The stock trades at a P\/E of 34.7, below the industry P\/E of 35.1. Looking ahead, the company uses cleaner, in-house developed processes that give it cost advantages in products such as MEHQ and guaiacol. It is adding new products and capacity, and carries no debt.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_crude_oil_drug_maker_and_chemical_stocks\"><\/span><strong>What risks should investors check before buying crude oil, drug maker and chemical stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying crude oil, drug maker and chemical stocks. Oil and gas prices. Earnings follow crude oil, gas and refining margins. Regulatory approvals. Plant inspections and approvals can affect supplies. Raw material and energy costs. Input prices can move margins in chemicals. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_crude_oil_drug_maker_and_chemical_stocks_investment_advice\"><\/span><strong>Is this list of crude oil, drug maker and chemical stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 17 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are crude oil, drug maker and chemical stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Crude oil, drug maker and chemical stocks are listed companies that produce crude oil and natural gas from fields in Assam and other basins, make branded medicines for India and global markets, and make performance chemicals for cosmetics, paints and pharma. Their earnings depend on oil prices, medicine demand and chemical orders. This list looks at three of them, Oil India, Ajanta Pharma and Clean Science and Technology, using reported FY22 to FY26 financials and the 17 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which crude oil, drug maker and chemical stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Oil India, Ajanta Pharma and Clean Science and Technology. Based on the 17 November 2026 close, Oil India traded at Rs 433.5, Ajanta Pharma at Rs 3,312.5 and Clean Science and Technology at Rs 715.95. Their return on equity ranges from 11.4% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.3% to 12.9%.\"}},{\"@type\":\"Question\",\"name\":\"Why do crude oil, drug maker and chemical stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Crude oil, drug maker and chemical stocks have a strong roadmap in India because steady energy demand, rising demand for branded medicines and wider use of specialty chemicals keep widening the market for these companies. The main drivers are as follows. Crude oil. The country needs home grown energy. Pharmaceuticals. Doctors prescribe trusted brands. Specialty chemicals. Brands need performance inputs. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Oil India performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 27,048 crore in FY22 to Rs 35,877 crore in FY26, a compound annual growth rate of 7.3%. Net profit grew from Rs 7,040 crore in FY25 to Rs 7,551 crore in FY26, a rise of 7.3%. In the June 2026 quarter, revenue grew 47.0% year on year to Rs 13,236 crore, while net profit rose 96.8% to Rs 4,027 crore. The company has a return on equity of 11.4%, a debt to equity ratio of 0.65 and a market capitalisation of Rs 72,563 crore. The stock trades at a P\/E of 7.6, above the industry P\/E of 7.2. Looking ahead, the company is stepping up exploration and development spending and building a presence in refining and clean energy through its group companies. Steady production supports earnings and dividends.\"}},{\"@type\":\"Question\",\"name\":\"How has Ajanta Pharma performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P\/E of 36.3, above the industry P\/E of 36.0. Looking ahead, the company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.\"}},{\"@type\":\"Question\",\"name\":\"How has Clean Science and Technology performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 715 crore in FY22 to Rs 989 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 230 crore, a net margin of 23.2%. In the June 2026 quarter, revenue grew 13.4% year on year to Rs 291 crore, while net profit rose 4.7% to Rs 73.3 crore. The company has a return on equity of 14.5%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 8,080 crore. The stock trades at a P\/E of 34.7, below the industry P\/E of 35.1. Looking ahead, the company uses cleaner, in-house developed processes that give it cost advantages in products such as MEHQ and guaiacol. It is adding new products and capacity, and carries no debt.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying crude oil, drug maker and chemical stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying crude oil, drug maker and chemical stocks. Oil and gas prices. Earnings follow crude oil, gas and refining margins. Regulatory approvals. Plant inspections and approvals can affect supplies. Raw material and energy costs. Input prices can move margins in chemicals. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of crude oil, drug maker and chemical stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 17 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Crude Oil, Drug Maker and Chemical Stocks with a strong future roadmap: Oil India, Ajanta Pharma and Clean Science and Technology. Compare price, valuation, return on equity and revenue growth as of 17 November 2026.<\/p>\n","protected":false},"author":35,"featured_media":353097,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[13959,3803,13951,4141,25838,25841,7159,20614,25839,25840],"class_list":["post-353099","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-ajanta-pharma","tag-best-stocks","tag-clean-science-and-technology","tag-crude-oil","tag-drug-maker-and-chemical-stocks","tag-formulations-and-specialty-chemicals-stocks","tag-oil-india","tag-oil-producer","tag-pharma-brand-and-performance-chemical-shares","tag-upstream-oil"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["353097"],"rank_math_title":["Crude Oil, Drug Maker and Specialty Chemical Stocks"],"rank_math_description":["Compare 3 crude oil, drug maker and chemical stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 17 Nov 2026."],"rank_math_focus_keyword":["crude oil, drug maker and chemical stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-crude-oil-producer-pharmaceuticals-company-and-specialty-chemicals-maker.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/353099","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=353099"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/353099\/revisions"}],"predecessor-version":[{"id":353100,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/353099\/revisions\/353100"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/353097"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=353099"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=353099"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=353099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}